MAPK3 and cancer: In this pathway, ERK1/2 is activated by the phosphorylation of the Thr202/Tyr204 site and subsequently phosphorylates numerous proteins involved in multiple malignant phenotypic features and ultimately aggravates cancer deterioration (40).